Elisabetta Antonioli

7.8k total citations
56 papers, 3.3k citations indexed

About

Elisabetta Antonioli is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Elisabetta Antonioli has authored 56 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 33 papers in Molecular Biology and 29 papers in Hematology. Recurrent topics in Elisabetta Antonioli's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Kruppel-like factors research (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Elisabetta Antonioli is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Kruppel-like factors research (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Elisabetta Antonioli collaborates with scholars based in Italy, United States and Germany. Elisabetta Antonioli's co-authors include Alessandro M. Vannucchi, Paola Guglielmelli, Tiziano Barbui, Alessandro Rambaldi, Guido Finazzi, Alberto Bosi, Alessandra Carobbio, Alessandro Pancrazzi, Ayalew Tefferi and Giovanni Barosi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Elisabetta Antonioli

52 papers receiving 3.3k citations

Peers

Countries citing papers authored by Elisabetta Antonioli

Since Specialization

Citations

This map shows the geographic impact of Elisabetta Antonioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Antonioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Antonioli more than expected).

Fields of papers citing papers by Elisabetta Antonioli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabetta Antonioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Antonioli. The network helps show where Elisabetta Antonioli may publish in the future.

Co-authorship network of co-authors of Elisabetta Antonioli

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Antonioli. A scholar is included among the top collaborators of Elisabetta Antonioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Antonioli. Elisabetta Antonioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? 2024 ·Expert Review of Hematology ·Massimo Martino, Barbara Gamberi, Elisabetta Antonioli, Sara Aquino, Roberta Della Pepa, Lara Malerba, Silvia Mangiacavalli, Sara Pezzatti, Sara Bringhen, Elena Zamagni	3
2	Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy 2024 ·SHILAP Revista de lepidopterología ·Francesca Fazio, Maria Teresa Petrucci, Laura Corvatta, Alfonso Piciocchi, Roberta Della Pepa, Paola Tacchetti, Maurizio Musso, Renato Zambello, Angelo Belotti, Sara Bringhen, Elisabetta Antonioli, Concetta Conticello, Nicola Di Renzo, Valerio De Stefano, Pellegrino Musto, Barbara Gamberi, Daniele Derudas, Mario Boccadoro, Massimo Offidani, (unknown)	1
3	Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports 2024 ·Cancer Reports ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alessandro M. Vannucchi, Elisabetta Antonioli	1
4	Ventricular tachyarrhythmias and sudden cardiac death in light‐chain amyloidosis: a clash of cardio‐toxicities? 2021 ·British Journal of Haematology ·Mattia Zampieri, Marco Allinovi, Iacopo Olivotto, Elisabetta Antonioli, (unknown), Alessia Argirò, Carlo Fumagalli, Giulia Nardi, Carlo Di Mario, Alessandro M. Vannucchi, Federico Perfetto, Francesco Cappelli	5
5	Lenalidomide: A double‐edged sword for concomitant multiple myeloma and post‐essential thrombocythemia myelofibrosis 2021 ·American Journal of Hematology ·Giuseppe Gaetano Loscocco, Elisabetta Antonioli, Ilaria Romano, Federica Vergoni, Giada Rotunno, Francesco Mannelli, Paola Guglielmelli, Alessandro M. Vannucchi	2
6	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria 2011 ·Leukemia ·Guido Finazzi, Alessandra Carobbio, J. Thiele, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi, Alessandro M. Vannucchi, Elisabetta Antonioli, Heinz Gisslinger, Veronika Buxhofer‐Ausch, Naseema Gangat, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui	131
7	Thrombosis in primary myelofibrosis: incidence and risk factors 2009 ·Blood ·Tiziano Barbui, Alessandra Carobbio, Francisco Cervantes, Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Alberto Álvarez‐Larrán, Alessandro Rambaldi, Guido Finazzi, Giovanni Barosi	196
8	Treatment options for essential thrombocythemia and polycythemia vera 2009 ·Expert Review of Hematology ·Alessandro M. Vannucchi, Paola Guglielmelli, Lisa Pieri, Elisabetta Antonioli, Alberto Bosi	4
9	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 2008 ·Blood ·Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Tiziano Barbui	79
10	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal 2008 ·Leukemia ·Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Animesh Pardanani, Ayalew Tefferi	215
11	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria 2007 ·Blood ·Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gayà, Luke Coyle, Carlos de Castro Lozano, Chieh‐Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, (unknown), Russell P. Rother, Peter Hillmen	457
12	Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey 2007 ·Blood ·Marco Ruggeri, Francesco Rodeghiero, Alberto Tosetto, Giancarlo Castaman, Francesca Scognamiglio, Guido Finazzi, Federica Delaini, Caterina Micò, Alessandro M. Vannucchi, Elisabetta Antonioli, Valerio De Stefano, Tommaso Zà, Luigi Gugliotta, Alessia Tieghi, Maria Gabriella Mazzucconi, Cristina Santoro, Tiziano Barbui	77
13	MicroRNA expression profile in granulocytes from primary myelofibrosis patients 2007 ·Experimental Hematology ·Paola Guglielmelli, Lorenzo Tozzi, Alessandro Pancrazzi, Costanza Bogani, Elisabetta Antonioli, Vanessa Ponziani, G Poli, Roberta Zini, Sérgio Ferrari, Rossella Manfredini, Alberto Bosi, Alessandro M. Vannucchi	61
14	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden 2007 ·Leukemia ·Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Giovanni Longo, Alessandro Pancrazzi, Vanessa Ponziani, Costanza Bogani, Pierluigi Rossi Ferrini, Alessandro Rambaldi, Vittoria Guerini, Alberto Bosi, Tiziano Barbui	279
15	Anaemia characterises patients with myelofibrosis harbouring Mpl^W515L/K mutation 2007 ·British Journal of Haematology ·Paola Guglielmelli, Alessandro Pancrazzi, Gaetano Bergamaschi, Vittorio Rosti, Laura Villani, Elisabetta Antonioli, Alberto Bosi, Giovanni Barosi, Alessandro M. Vannucchi	103
16	A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis 2006 ·Leukemia ·Alessandro M. Vannucchi, Alessandro Pancrazzi, Costanza Bogani, Elisabetta Antonioli, Paola Guglielmelli	54
17	Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study 2006 ·British Journal of Haematology ·Giacomo Gianfaldoni, Francesco Mannelli, Michela Baccini, Elisabetta Antonioli, Franco Leoni, Alberto Bosi	34
18	Chronic Relapsing Thrombotic Thrombocytopenic Purpura Successfully Treated with Rituximab: Case Report 2005 ·Journal of Chemotherapy ·Giacomo Gianfaldoni, Elisabetta Antonioli, Francesco Mannelli, (unknown), Alberto Bosi	3
19	Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma 2005 ·British Journal of Haematology ·Alessandro M. Vannucchi, Giuseppe Ficarra, Elisabetta Antonioli, Alberto Bosi	88
20	PRV‐1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia 2004 ·British Journal of Haematology ·Alessandro M. Vannucchi, Alberto Grossi, Alessandro Pancrazzi, Elisabetta Antonioli, Paola Guglielmelli, (unknown), (unknown), (unknown), Giovanni Longo, Claudio Graziano, Luigi Gugliotta, Alberto Bosi	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact